News | Virtual and Augmented Reality | October 01, 2020

FDA Clears First Holographic Cardiac Ablation Guidance System

SentiAR 510(k) Clearance of CommandEP System enables augmented reality 3-D imaging of the heart

The FDA granted 510(k) clearance for the SentiAR CommandEP system, the first holographic guidance system to be used during an invasive electrophysiology (EP) lab cardiac procedures. The system allows electrophysiologists to visualize 3-D electro-anatomic models in real-time, via a wearable headset and offer a truly handsfree control interface providing superior visualization, allowing them to navigate accurately within the heart during a cardiac ablation procedure.

The FDA granted 510(k) clearance for the SentiAR CommandEP system, the first holographic guidance system to be used during an invasive electrophysiology (EP) lab cardiac procedures. The system allows electrophysiologists to visualize 3-D electro-anatomic models in real-time, via a wearable headset and offer a truly handsfree control interface providing superior visualization, allowing them to navigate accurately within the heart during a cardiac ablation procedure.


October 1, 2020 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the SentiAR CommandEP system, the first holographic guidance system to be used during an invasive electrophysiology (EP) lab cardiac procedures. The CommandEP system allows electrophysiologists to visualize 3-D electro-anatomic models in real-time, via a wearable headset and offer a truly handsfree control interface providing superior visualization, allowing them to navigate accurately within the heart during a cardiac ablation procedure.

The CommandEP system receives imaging data from the electro-anatomic mapping systems and creates a 3-D holographic image via SentiAR's proprietary data flow and visualization algorithms. This patented system presents a 3-D image of the patient's heart showing the real-time position of the catheters within to the physicians via a wearable headset, currently Microsoft HoloLens. Additionally, SentiAR deploys its unique, trade-secret augmented reality (AR) engine to deliver uncompromising performance.

SentiAR successfully completed a clinical study with the CommandEP system at St. Louis Children's and Barnes Jewish Hospitals. During the procedure with CommandEP, physicians were asked to perform a navigation study by targeting specific points within the patient anatomy. Each navigation exercise was completed with the CommandEP system and repeated again with standard visualization tools. The results of the comparative analysis showed a 44% reduction in mean navigation error with the CommandEP system over standard visualization tools. The results of this study were published in Journal of American College of Cardiology: Clinical Electrophysiology.[1]

"The addition of SentiAR's holographic guidance system provides electrophysiologists with a game-changing platform for mapping and interventional procedures," said John K. Triedman, M.D., chief of cardiac clectrophysiology at Boston Children's Hospital. "The ability to see the models in 3D in real-time, to look inside chambers and around corners while moving and rotating the model allows us to gain a better and more precise understanding of cardiac anatomy. We anticipate being able to easily integrate the CommandEP system with our existing EP lab workflows. The powerful tools CommandEP provides have real potential to allow electrophysiologists to perform more accurate procedures."

"CommandEP represents a huge leap forward in cardiac ablation technology," said Paul Buckman, member of the board of directors of SentiAR. "Our clinical and strategic partners are thrilled with the patient data showing improved navigation, and together we look forward to putting CommandEP into the hands of electrophysiologists worldwide."

"SentiAR's holographic ablation guidance system is our first of many products that will revolutionize interventional procedures," said Berk Tas, CEO of SentiAR. "SentiAR provides physicians superhuman capabilities to integrate their digital environments so they can focus on patients and their treatment."

The CommandEP system is now available for sale in the United States with distribution expected to begin in 2021.

For more information: https://sentiar.com/#!about

 

Reference:

1. Jennifer N. Avari Silva, Michael K.Southworth, Walter M.Blume, et al. First-In-Human Use of a Mixed Reality Display During Cardiac Ablation Procedures. JACC: Clinical Electrophysiology. Volume 6, Issue 8, August 2020, Pages 1023-1025. https://doi.org/10.1016/j.jacep.2020.04.036.

Related Content

News | EP Lab

January 14, 2022 — Medtronic has entered into a definitive agreement to acquire Affera Inc., a Boston area-based ...

Home January 14, 2022
Home
News | EP Lab

January 13, 2022 — Abbott received U.S. Food and Drug Administration (FDA) clearance for the EnSite X EP System with ...

Home January 13, 2022
Home
News | EP Lab

January 7, 2022 — Khaldoun Tarakji, M.D., M.P.H., associate section head of cardiac electrophysiology at the Heart ...

Home January 07, 2022
Home
News | EP Lab

January 5, 2022 — Stereotaxis announced a recent publication in Frontiers in Cardiovascular Medicine titled “Atrial ...

Home January 05, 2022
Home
Feature | EP Lab

Children’s Hospital Los Angeles cardiologist Michael Silka, M.D., helped to pioneer the development of indications for ...

Home December 07, 2021
Home
News | EP Lab

November 22, 2021 — BioSig Technologies Inc., a medical technology company commercializing an innovative biomedical ...

Home November 22, 2021
Home
Videos | EP Lab

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz ...

Home November 22, 2021
Home
Feature | EP Lab

November 18, 2021 — The U.S. Food and Drug Administration (FDA) is reminding providers about the risk of major ...

Home November 18, 2021
Home
News | EP Lab

November 16, 2021 — Acutus Medical Inc. (Acutus), an arrhythmia management company focused on improving the way cardiac ...

Home November 16, 2021
Home
News | EP Lab

November 15, 2021 — Vektor Medical Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Home November 15, 2021
Home
Subscribe Now